Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 9 (September)

1. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
   Cancer Immunol Immunother, 55(12): 1524-33. [Abstract] [Full-text]
2. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
   Hum Mutat, 27(10): 1062-3. [Abstract] [Full-text]
3. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
   Prostate, 66(13): 1359-70. [Abstract] [Full-text]
4. Screening of genetic and expression alterations of SRC1 gene in prostate cancer.
   Prostate, 66(13): 1391-8. [Abstract] [Full-text]
5. Immunohistochemical characterization of neuroendocrine cells in prostate cancer.
   Prostate, 66(13): 1399-406. [Abstract] [Full-text]
6. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study.
   Am J Epidemiol, 164(6): 549-55. [Abstract] [Full-text]
7. Human laminin-5 and laminin-10 mediated gene expression of prostate carcinoma cells.
   Prostate, 66(13): 1381-90. [Abstract] [Full-text]
8. Obesity and prostate cancer screening among African-American and Caucasian men.
   Prostate, 66(13): 1371-80. [Abstract] [Full-text]
9. Mechanism of 2-chloroadenosine toxicity to PC3 cell line.
   Prostate, 66(13): 1425-36. [Abstract] [Full-text]
10. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence.
    Prostate, 66(13): 1437-44. [Abstract] [Full-text]
11. The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells.
    Prostate, 66(13): 1413-24. [Abstract] [Full-text]
12. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.
    Prostate, 66(13): 1455-62. [Abstract] [Full-text]
13. Identification of both Myt-1 and Wee-1 as necessary mediators of the p21-independent inactivation of the cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein.
    Prostate, 66(14): 1542-55. [Abstract] [Full-text]
14. Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis.
    Prostate, 66(14): 1535-41. [Abstract] [Full-text]
15. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
    Prostate, 66(14): 1512-20. [Abstract] [Full-text]
16. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
    Prostate, 66(14): 1498-511. [Abstract] [Full-text]
17. Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.
    Prostate, 66(14): 1487-97. [Abstract] [Full-text]
18. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study.
    Prostate, 66(14): 1556-64. [Abstract] [Full-text]
19. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.
    Prostate, 66(14): 1474-86. [Abstract] [Full-text]
20. Quantitative multi-gene expression profiling of primary prostate cancer.
    Prostate, 66(14): 1521-34. [Abstract] [Full-text]
21. Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells.
    J Cell Physiol, 209(2): 522-34. [Abstract] [Full-text]
22. Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3.
    Prostate, 66(14): 1463-73. [Abstract] [Full-text]
23. Potential biomarker for early risk assessment of prostate cancer.
    Prostate, 66(14): 1565-71. [Abstract] [Full-text]
24. 1,25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells.
    J Cell Physiol, 209(2): 363-9. [Abstract] [Full-text]
25. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation.
    J Urol, 176(4): 1648-53. [Abstract] [Full-text]
26. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand.
    J Urol, 176(4): 1558-63; discussion 1563-4. [Abstract] [Full-text]
27. Time to return to work and physical activity following open radical retropubic prostatectomy.
    J Urol, 176(4): 1420-3. [Abstract] [Full-text]
28. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    J Urol, 176(4): 1415-9. [Abstract] [Full-text]
29. E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
    J Urol, 176(4): 1409-14; discussion 1414. [Abstract] [Full-text]
30. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    J Urol, 176(4): 1404-8. [Abstract] [Full-text]
31. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    J Urol, 176(4): 1399-403. [Abstract] [Full-text]
32. Modeling prostate specific antigen kinetics in patients on active surveillance.
    J Urol, 176(4): 1392-7; discussion 1397-8. [Abstract] [Full-text]
33. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
    J Urol, 176(4): 1387-91. [Abstract] [Full-text]
34. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE.
    J Urol, 176(4): 1382-6. [Abstract] [Full-text]
35. Re-biopsy of the prostate using a stereotactic transperineal technique.
    J Urol, 176(4): 1376-81; discussion 1381. [Abstract] [Full-text]
36. Metastatic prostate cancer-does treatment of the primary tumor matter?
    J Urol, 176(4): 1292-8. [Abstract] [Full-text]
37. Bladder/prostate rhabdomyosarcoma: past, present and future.
    J Urol, 176(4): 1283-91. [Abstract] [Full-text]
38. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.
    Genes Chromosomes Cancer, 45(11): 1018-32. [Abstract] [Full-text]
39. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells.
    Int J Cancer, 119(9): 2071-7. [Abstract] [Full-text]
40. PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer.
    Bioinformatics, 22(18): 2269-75. [Abstract] [Full-text]
41. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.
    Biochem Biophys Res Commun, 349(1): 372-82. [Abstract] [Full-text]
42. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth.
    J Cell Physiol, 208(3): 566-74. [Abstract] [Full-text]
43. Quality assurance of I-125 seeds for prostate brachytherapy using an imaging plate.
    Int J Radiat Oncol Biol Phys, 66(2): 603-9. [Abstract] [Full-text]
44. Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 66(2): 597-602. [Abstract] [Full-text]
45. Daily variations in the position of the prostate bed in patients with prostate cancer receiving postoperative external beam radiation therapy.
    Int J Radiat Oncol Biol Phys, 66(2): 593-6. [Abstract] [Full-text]
46. Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(2): 583-92. [Abstract] [Full-text]
47. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.
    Int J Radiat Oncol Biol Phys, 66(2): 439-44. [Abstract] [Full-text]
48. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
    Int J Radiat Oncol Biol Phys, 66(2): 389-94. [Abstract] [Full-text]
49. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(2): 382-8. [Abstract] [Full-text]
50. Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique.
    Int J Radiat Oncol Biol Phys, 66(2): 430-8. [Abstract] [Full-text]
51. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(2): 395-402. [Abstract] [Full-text]
52. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease.
    Int J Radiat Oncol Biol Phys, 66(2): 424-9. [Abstract] [Full-text]
53. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(2): 408-15. [Abstract] [Full-text]
54. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
    Int J Radiat Oncol Biol Phys, 66(2): 416-23. [Abstract] [Full-text]
55. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 66(2): 403-7. [Abstract] [Full-text]
56. ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.
    Oncogene, 25(41): 5591-600. [Abstract] [Full-text]
57. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.
    Mol Cell Biol, 26(19): 7331-41. [Abstract] [Full-text]
58. Lipofuscin pigment can be used as a prognostic marker in prostatic adenocarcinoma.
    Ann Diagn Pathol, 10(5): 257-62. [Abstract] [Full-text]
59. Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes.
    BJU Int, 98(4): 907-11. [Abstract] [Full-text]
60. The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer.
    BJU Int, 98(4): 903-6. [Abstract] [Full-text]
61. Gene expression profiling of the human prostate zones.
    BJU Int, 98(4): 886-97. [Abstract] [Full-text]
62. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study.
    BJU Int, 98(4): 794-7. [Abstract] [Full-text]
63. African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
    BJU Int, 98(4): 783-7. [Abstract] [Full-text]
64. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    BJU Int, 98(4): 777-82. [Abstract] [Full-text]
65. Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells.
    Biochem Biophys Res Commun, 349(2): 789-98. [Abstract] [Full-text]
66. The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy.
    BJU Int, 98(4): 770-2. [Abstract] [Full-text]
67. Identification of the retrotrigonal layer as a key anatomical landmark during robotically assisted radical prostatectomy.
    BJU Int, 98(4): 829-32. [Abstract] [Full-text]
68. Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells.
    Endocrinology, 147(10): 4599-607. [Abstract] [Full-text]
69. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells.
    Endocrinology, 147(10): 4883-92. [Abstract] [Full-text]
70. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    BJU Int, 98(4): 788-93. [Abstract] [Full-text]
71. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
    Endocrinology, 147(10): 4960-7. [Abstract] [Full-text]
72. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made.
    J Clin Oncol, 24(27): 4457-63. [Abstract] [Full-text]
73. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    J Clin Oncol, 24(27): 4448-56. [Abstract] [Full-text]
74. Tocopherols and saponins derived from Argania spinosa exert, an antiproliferative effect on human prostate cancer.
    Cancer Invest, 24(6): 588-92. [Abstract] [Full-text]
75. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Cancer, 107(6): 1265-72. [Abstract] [Full-text]
76. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells.
    J Nutr Biochem, 17(10): 689-96. [Abstract] [Full-text]
77. Gastrointestinal stromal tumor of the prostate: a case report and literature review.
    Hum Pathol, 37(10): 1361-5. [Abstract] [Full-text]
78. Sarcomatoid carcinoma of the prostate: a study of 42 cases.
    Am J Surg Pathol, 30(10): 1316-21. [Abstract] [Full-text]
79. Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases.
    Am J Surg Pathol, 30(10): 1254-9. [Abstract] [Full-text]
80. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
    Am J Surg Pathol, 30(10): 1231-6. [Abstract] [Full-text]
81. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.
    Proc Natl Acad Sci U S A, 103(39): 14477-82. [Abstract] [Full-text]
82. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation.
    Proc Natl Acad Sci U S A, 103(39): 14519-24. [Abstract] [Full-text]
83. Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha.
    Biochem Biophys Res Commun, 349(4): 1361-7. [Abstract] [Full-text]
84. Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy.
    Prostate, 66(15): 1620-30. [Abstract] [Full-text]
85. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Prostate, 66(15): 1573-84. [Abstract] [Full-text]
86. Increased expression of the metastasis-associated gene Ehm2 in prostate cancer.
    Prostate, 66(15): 1641-52. [Abstract] [Full-text]
87. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
    Prostate, 66(15): 1653-63. [Abstract] [Full-text]
88. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
    Prostate, 66(15): 1674-85. [Abstract] [Full-text]
89. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity.
    Prostate, 66(15): 1631-40. [Abstract] [Full-text]
90. Molecular cloning and functional study of rat estrogen receptor-related receptor gamma in rat prostatic cells.
    Prostate, 66(15): 1600-19. [Abstract] [Full-text]
91. Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer.
    Prostate, 66(15): 1585-91. [Abstract] [Full-text]
92. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis.
    Prostate, 66(15): 1664-73. [Abstract] [Full-text]
93. trans-10,cis-12 conjugated linoleic acid inhibits the G1-S cell cycle progression in DU145 human prostate carcinoma cells.
    J Med Food, 9(3): 293-9. [Abstract] [Full-text]
94. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
    Oncogene, 25(44): 5942-52. [Abstract] [Full-text]
95. Do patients with localized prostate cancer treatment really want more aggressive treatment?
    J Clin Oncol, 24(28): 4581-6. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.